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PREFACE 
Drinking Water Public Health Goals 
Pesticide and Environmental Toxicology Section 
Office of Environmental Health Hazard Assessment 
California Environmental Protection Agency 
This Public Health Goal (PHG) technical support document provides information on 
health effects from contaminants in drinking water.  PHGs are developed for chemical 
contaminants based on the best available toxicological data in the scientific literature. 
These documents and the analyses contained in them provide estimates of the levels of 
contaminants in drinking water that would pose no significant health risk to individuals 
consuming the water on a daily basis over a lifetime. 
The California Safe Drinking Water Act of 1996 (amended Health and Safety Code, 
Section 116365), amended 1999, requires the Office of Environmental Health Hazard 
Assessment (OEHHA) to perform risk assessments and publish PHGs for contaminants 
in drinking water based exclusively on public health considerations.  Section 116365 
specifies that the PHG is to be based exclusively on public health considerations without 
regard to cost impacts.  The Act requires that PHGs be set in accordance with the 
following criteria: 
1. 	 PHGs for acutely toxic substances shall be set at levels at which no known or 
anticipated adverse effects on health will occur, with an adequate margin of 
safety. 
2. 	 PHGs for carcinogens or other substances which can cause chronic disease shall 
be based upon currently available data and shall be set at levels which OEHHA 
has determined do not pose any significant risk to health. 
3. 	 To the extent the information is available, OEHHA shall consider possible 
synergistic effects resulting from exposure to two or more contaminants. 
4. 	 OEHHA shall consider the existence of groups in the population that are more 
susceptible to adverse effects of the contaminants than a normal healthy adult. 
5. 	 OEHHA shall consider the contaminant exposure and body burden levels that 
alter physiological function or structure in a manner that may significantly 
increase the risk of illness. 
6. 	 In cases of insufficient data to determine a level of no anticipated risk, OEHHA 
shall set the PHG at a level that is protective of public health with an adequate 
margin of safety. 
7. 	 In cases where scientific evidence demonstrates that a safe dose-response 
threshold for a contaminant exists, then the PHG should be set at that threshold. 
8. 	 The PHG may be set at zero if necessary to satisfy the requirements listed above. 
DRAFT FOR PUBLIC COMMENT 

AND SCIENTIFIC REVIEW  ii 	 June 2002  
 
 
 DRAFT
 
9. 	 OEHHA shall consider exposure to contaminants in media other than drinking 
water, including food and air and the resulting body burden. 
10. 	 PHGs published by OEHHA shall be reviewed every five years and revised as 
necessary based on the availability of new scientific data. 
PHGs published by OEHHA are for use by the California Department of Health Services 
(DHS) in establishing primary drinking water standards (State Maximum Contaminant 
Levels, or MCLs).  Whereas PHGs are to be based solely on scientific and public health 
considerations without regard to economic cost considerations, drinking water standards 
adopted by DHS are to consider economic factors and technical feasibility.  Each 
standard adopted shall be set at a level that is as close as feasible to the corresponding 
PHG, placing emphasis on the protection of public health.  PHGs established by OEHHA 
are not regulatory in nature and represent only non-mandatory goals.  By federal law, 
MCLs established by DHS must be at least as stringent as the federal MCL if one exists. 
PHG documents are used to provide technical assistance to DHS, and they are also 
informative reference materials for federal, state and local public health officials and the 
public.  While the PHGs are calculated for single chemicals only, they may, if the 
information is available, address hazards associated with the interactions of contaminants 
in mixtures.  Further, PHGs are derived for drinking water only and are not to be utilized 
as target levels for the contamination of other environmental media.  
Additional information on PHGs can be obtained at the OEHHA Web site at 
www.oehha.ca.gov. 
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PUBLIC HEALTH GOAL FOR TOXAPHENE IN 

DRINKING WATER
 
SUMMARY 
A Public Health Goal (PHG) of 0.00003 mg/L (0.03 ppb) is proposed for toxaphene 
in drinking water.  Toxaphene is an organochlorine pesticide consisting of a complex 
mixture of chlorinated camphenes used to control a broad range of insects on diverse 
crops.  Toxaphene has not been used worldwide for many years, but is found in the 
environment as residues in sediments and soil.  The characteristic toxicity of 
toxaphene is injury to the liver, kidney and nervous system.  In particular, it has been 
identified as an animal carcinogen based on chronic studies conducted in several 
species. 
In 1991, OEHHA developed a Recommended Public Health Level (RPHL) for 
toxaphene based on our earlier evaluation of toxaphene carcinogenicity for 
Proposition 65 (OEHHA, 1988).  The potency calculation was based on evidence for 
carcinogenicity in a chronic mouse study.  In this study (Litton, 1978), B6C3F1 mice 
were administered toxaphene at 0, 7, 20, or 50 ppm in the diet for 18 months.  The 
average daily doses are calculated to be 0, 0.84, 2.4, and 6.0 mg/kg-day, respectively, 
based on the assumption that 1 ppm of a chemical in feed is equivalent to 
0.12 mg/kg-day dose.  An increase in the incidence of hepatocellular carcinoma was 
observed in treated male mice.  The tumor incidences were 10/53, 11/54, 12/53 and 
18/51 for the male control, 7, 20 and 50 ppm treatment groups, respectively.  Fitting 
the multistage polynomial to these data resulted in a cancer potency for animals 
(qanimal) of 0.905 (mg/kg-day)
-1, and for humans (qhuman) of 1.2 (mg/kg-day)
-1.  Based 
on the cancer potency of 1.2 (mg/kg-day)
-1 and a one in a million cancer risk level, 
with the default assumption that a 70- kg adult consumes two liters of water a day, 
the health-protective level was set at 30 ng/L (0.03 ppb). 
Since there have been no new studies which would indicate more sensitive effects 
from chronic exposure to toxaphene or alter the previous interpretation, the 
assessment of health protective level in drinking water has not been changed.  The 
proposed PHG for toxaphene in drinking water is 0.03 ppb.  The current MCL of 
0.003 mg/L (3 ppb) for toxaphene in drinking water is based on carcinogenic effects 
of toxaphene, subject to the sensitivity of approved analytical methodology to 
monitor toxaphene in water. 
INTRODUCTION 
The purpose of this document is to propose a PHG for toxaphene (and its residual 
products) in drinking water.  In the past, toxaphene was used widely in agricultural 
applications throughout California.  Its use has been severely restricted since 1981, 
and all uses were banned in 1990.  However, because of its previous extensive use 
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and its relative persistence in the environment, it may contaminate water supplies 
and pose a hazard in drinking water.  Federal and state drinking water regulations 
have been developed for toxaphene.  A federal Maximum Contaminant Level (MCL) 
of 0.003 mg/L was promulgated for toxaphene (U.S. EPA, 1991).  The same value 
was adopted by the California Department of Health Services (DHS) as the state 
MCL (22 CCR 64444).  This MCL value is based on analytical detection 
methodology for toxaphene and represents the cancer risk at the 10
-4 level.  The 
toxaphene health-protective level of 0.003 ppb proposed by OEHHA (1991) was 
based on the cancer risk level of 10
-6. 
U.S. EPA stated that there is evidence that toxaphene has the potential to cause 
cancer from lifetime exposures in drinking water (U.S. EPA, 1999).  There is also an 
evaluation of carcinogenicity in IRIS (IRIS, 1999).  Under California's Proposition 
65, toxaphene is considered a substance known to the State to cause cancer (22 CCR 
12000). 
This document focuses on evaluating the available data on the toxicity of toxaphene.  
To determine a public health-protective level of toxaphene in drinking water, 
sensitive groups were identified and considered, and relevant studies were identified, 
reviewed and evaluated. 
CHEMICAL PROFILE 
Chemical Identity 
Toxaphene is a complex organochlorine pesticide consisting of chlorinated 
camphenes with a wide range of molecular weights. Other information related to the 
identity of toxaphene is provided in Table 1. 
Physical and Chemical Properties 
Toxaphene is a mixture of polychlorinated compounds, appearing as a waxy solid 
with limited solubility in water.  Important physical and chemical properties of 
toxaphene are provided in Table 1.  Representative structures of toxaphene 
congeners are provided in Figure 1. 
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Table 1.  Identity and Chemical/Physical Properties of Toxaphene (ATSDR, 
1996) 
Property  Value or Information 
Chemical name(s)  Toxaphene, camphechlor; chlorinated 
camphene 
Chemical formula  C10H10Cl8 (average; includes components 
with 6 to 9 chlorines) 
Molecular weight  414 (average) 
CAS number  8001-35-2 
EPA hazardous waste code  P123 
Trade names  Agricide Maggot Killer, Alltox; Camphofene 
Huilex, Geniphene, Hercules 3956, Hercules 
Toxaphene, Motto, Penphene, Phenicide, 
Phenatox, Strobane-T, Synthetic 3956, 
Toxakil 
Color/Form/Odor  Yellow waxy solid with mild turpentine odor 
Melting point
a  65-90 °C 
Vapor pressure
a  0.2-0.4 or 4 x 10
-6, 5 x 10
-6, 3 x 10
-7 mm Hg 
at 20 °C 
Octanol /Water partition (Kow)  3.3 Log Kow 
Density/Specific gravity  1.65 at 25 °C 
Solubility  0.0003 g/100 mL water 
Odor/Taste thresholds  NA 
Bioconcentration factor  NA 
a The wide range of values may represent different toxaphene mixtures. 
NA: not available 
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Figure 1.  Representative Structures for Toxaphene (from Pollock and Kilgore 
(1978).  [Note: the nomenclature used here is the authors’; for an extensive 
discussion regarding nomenclature for toxaphene congeners see De Geus et al. 
(1999)]. 
Production and Uses 
Toxaphene is a mixture of at least 670 chlorinated bicyclic terpenes (ATSDR, 1996).  
Technical grade toxaphene is made from technical grade camphene reacted with 
chlorine gas using ultraviolet radiation and catalysts.  Technical grade toxaphene was 
available in various forms: a solid, a 90 percent solution in xylene or oil, wettable 
powder, granules, dusts, and emulsifiable concentrates (ATSDR, 1996). 
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Toxaphene was produced in the early 1940s for insect control, some acaricidal 
properties and control of undesirable aquatic species (ATSDR, 1996).  It was largely 
used on grain crops, particularly corn and soybeans, and on cotton.  Increased use 
occurred in the late 1960s to early 70s when it replaced DDT in formulations 
combined with methyl parathion.  Toxaphene was at one time the most heavily 
manufactured pesticide in the United States with a maximum production volume of 
23,000 tons in 1973 (ATSDR, 1996).  Due to its potential for environmental effects 
and toxicity, U.S. EPA cancelled registration for most uses in 1982 and allowed 
existing stocks to be depleted.  In 1990, all remaining uses were cancelled and 
existing stocks could not be sold (ATSDR, 1996).  By 1993 all tolerances and food 
additive regulations for toxaphene on all agricultural commodities were revoked 
(U.S. EPA, 1999). 
ENVIRONMENTAL OCCURRENCE AND HUMAN EXPOSURE 
Air 
As a result of its widespread use, toxaphene has been distributed to all environmental 
media.  In aerial and ground applications, toxaphene was released directly to the 
atmosphere.  This release and subsequent persistence of airborne toxaphene resulted 
from the relatively volatile nature of the toxaphene as well as its resistance to direct 
photolysis.  Removal of toxaphene from the atmosphere occurs principally by 
deposition of toxaphene bound to particles (ATSDR, 1996). 
As a complex mixture of congeners, toxaphene formulations would be expected to 
have variable volatilities and degradation patterns complicating the monitoring of 
toxaphene in the environment.  However, researchers have been able to identify 
toxaphene fractions and confirm its widespread airborne transport in remote areas of 
the Canadian Arctic and the South Atlantic Ocean (ATSDR, 1996). 
Soil 
Toxaphene strongly adsorbs to soils and particles.  Once bound, toxaphene may 
persist in soils, especially surface soils, for over two months (Seiber et al., 1979).  
Disappearance from surface soils appears to be primarily by volatilization, although 
some congeners appeared to be degraded (Seiber et al., 1979).  Other studies have 
indicated that degradation of toxaphene, primarily by dechlorination, generally 
occurs under anaerobic rather than aerobic conditions (ATSDR, 1996). 
Water 
Deposition of airborne toxaphene and/or its direct application to lakes and streams to 
eliminate undesirable species has resulted in the detection of significant quantities in 
surface waters.  Toxaphene, however, has low water solubility (3 mg/L), strongly 
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binds to particles, and is deposited into sediments.  Thus, it has been argued that 
significant ground water contamination should not occur.  However, toxaphene has 
been detected in ground water as a result of normal agricultural use (ATSDR, 1996). 
In water, toxaphene appears to be resistant to all forms of degradation.  It is not 
known to undergo photolysis or photooxidation.  Hydrolysis of toxaphene is 
insignificant; a hydrolytic half-life of 10 years was estimated for water at pH 5 to 8 
(U.S. EPA, 1985).  Nationwide, toxaphene has rarely been detected in public water 
supplies.  In Flint Creek, Alabama, water supplies, toxaphene concentrations ranged 
from 0.05 to 0.410 ppb (ATSDR, 1996).  In California, toxaphene was detected in 
only 2 of 5,279 public drinking water supplies sampled from 1984-1992 (Storm, 
1994).  In the most recent ground water survey (1996-1997) conducted by the 
California Department of Pesticide Regulation, toxaphene was not detected in the 
sampling of wells (DPR, 1998). 
Food 
Residues of toxaphene congeners have been detected on raw and finished 
agricultural commodities.  At one time, primarily during the 1980s, toxaphene was 
one of the most commonly detected pesticides in food commodities (ATSDR, 1996).  
However, in the decade since its registration was suspended, detections have fallen 
off dramatically.  In the Food and Drug Administration’s Annual Food Survey of 
1990 (FDA, 1991), toxaphene residues were detected in 2 percent of food tested.  In 
the 1999 Survey, no detection of residues was reported (FDA, 2000). 
Although toxaphene exposure from agriculturally derived food sources has dropped, 
concern over toxaphene exposure from seafood remains.  It has been established 
through laboratory bioassay and field monitoring data that toxaphene congeners are 
bioconcentrated by aquatic organisms (ATSDR, 1996).  However, biomagnification 
is limited by metabolism of higher trophic organisms.  Therefore, toxaphene is not 
thought to be as severe a biomagnification problem as are PCBs or dioxins.  Even so, 
ingestion of seafood remains a food source for human toxaphene exposure, but to a 
lesser extent. 
Other Sources 
Toxaphene use has been banned in the United States and Western European 
countries, but it is not clear whether other countries are continuing to use it, or to 
what extent (ATSDR, 1996).  Thus toxaphene may continue to be disseminated in 
the global environment. 
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METABOLISM AND PHARMACOKINETICS 
Absorption 
There are a limited number of studies of toxaphene absorption from all routes of 
exposure.  Toxaphene is likely to be taken up readily by all routes of exposure based 
on its physical properties (small size and lipophilicity) and the detection of 
toxaphene congeners and metabolites in body tissues and fluids. 
Oral absorption of toxaphene appears to be enhanced when taken together with oily 
foods (ATSDR, 1996). 
Distribution 
Upon absorption, toxaphene becomes concentrated in fatty tissues.  Pollock and 
Kilgore (1980) administered 
14C toxaphene at 10 mg/kg in olive oil to rats.  Seven 
days later, 6.4 mg/kg of toxaphene and its metabolites were found in the fat, while 
the remaining tissues had less than 0.2 mg/kg.  Administering radiolabeled 
toxaphene in peanut oil to rats resulted in high concentrations of toxaphene residues 
initially in brown fat and also in the adrenal cortex, bone marrow, liver and kidney, 
which peaked at three hours (Mohammed et al., 1985).  After 24 hours, radioactivity 
was found mostly in the white fat, with lesser amounts in the liver and kidney. 
Metabolism 
Studies indicate that toxaphene is rapidly and extensively degraded in vivo. 
Metabolism appears to occur entirely in the liver and consists of dechlorination, 
dehydrochlorination and oxidation.  Products are eliminated primarily through the 
feces, although there is significant urinary excretion. 
Ohsawa et al. (1975) noted that upon oral administration of radiolabeled (both 
chlorine and carbon) toxaphene to rats, about 50 percent of the label was eliminated 
in the urine as chloride ion along with some unmetabolized product within fourteen 
days.  A small amount was exhaled as carbon dioxide.  The rest of the urinary 
products were metabolites of toxaphene.  Pollock and Kilgore (1980) demonstrated 
that all metabolic components in the urine were more polar than toxaphene.  
Due to the complex nature of toxaphene, certain components would be either more 
or less resistant to metabolism, resulting in different metabolic fates.  This 
complicates understanding the metabolic pathways of toxaphene.  Thus the study of 
pathways of metabolism has been limited to the study of selected components of 
toxaphene. 
Saleh et al. (1979) evaluated the metabolism of one component of toxaphene, termed 
‘toxicant B,’ in several species and noted that monkey and rabbit had the most 
extensive metabolism of ‘toxicant B’ as compared with mice, rats, hamster, guinea 
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pigs and chickens.  Rat liver microsomes, in the presence of NADPH under 
anaerobic conditions, were able to dechlorinate toxicant B.  The presence of fecal 
metabolites and the understanding that toxicant B was metabolized to a greater 
extent under anaerobic conditions, suggests that metabolism of this component was 
occurring in the intestine (Saleh et al., 1979). 
Excretion 
Toxaphene is rapidly eliminated from the body.  Crowder and Dindal (1974) noted 
about 50 percent of a 20 mg dose of toxaphene given to rats was excreted in 9 days.  
About 70 percent of the excreted dose was found in the feces and 30 percent in the 
urine. 
Pollock and Hillstrand (1982) evaluated the excretion of radiolabeled toxaphene in 
pregnant and virgin female rats.  After administration of 2.6 mg/kg of toxaphene in 
olive oil, about 50 percent of the total activity was recovered in the urine and feces 
after five days. The additional fatty tissue present in pregnant rats did not appear to 
change the retention of toxaphene or its metabolites. 
TOXICOLOGY 
Toxicological Effects in Animals 
Acute Toxicity 
Toxaphene stimulates the central nervous system at high doses like other chlorinated 
hydrocarbon pesticides.  The range of oral lethal values (LD50s) was 80 to 295 mg/kg 
for rats (ATSDR, 1996).  Two out of eight dogs died after receiving 15 mg/kg 
toxaphene in corn oil.  However when the vehicle was kerosene, death did not occur 
until the dose reached 200 mg/kg in one of five dogs (Lackey, 1949). 
Subchronic Toxicity 
Toxaphene toxicity has been evaluated in a number of short-term studies.  Peakall 
(1976) described two studies.  In one, rats were given an oral dose of 120 mg 
toxaphene/kg and monitored for up to 15 days.  Liver weight and microsomal 
enzyme activity increased after 5 and 15 days, respectively.  Other rats were given 
toxaphene at 2.4 mg/kg per day for one, three, and six months.  Liver and body 
weights increased at all time intervals compared to controls, but plasma testosterone 
levels were not affected. 
In the NCI (1977) subchronic study, groups of five mice or rats of each sex were 
given toxaphene added to feed at concentrations of 150 to 2,560 ppm for rats and 40 
to 1,280 ppm for mice for six weeks.  A second study was performed on male and 
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female rats with the same parameters as the first study but at concentrations from 
1,280 to 5,120 ppm, to extend the first study.  Controls for both studies consisted of 
five animals per group administered only feed.  Mean weight gains for treated 
animals were comparable to that of controls.  In both rat studies, no deaths occurred 
at concentrations below 2,560 ppm.  Deaths occurred in the mouse study only at 640 
and 320 ppm, but not at the highest dose, thereby suggesting no dose-related lethal 
effects. 
Adult male rats were fed toxaphene in diets at concentrations of 0, 50, 100, 150 or 
200 ppm diet for 14 days (Trottman and Desaiah, 1980).  No changes were observed 
in body weight gain, food consumption, brain, kidney, heart, or testes weights.  Liver 
weight was increased at 200 ppm and thymus weight decreased at 150 and 200 ppm 
(estimated doses: 7.5 and 10 mg/kg). 
In another study (Chu et al., 1986), ten male and female rats were fed diets 
containing toxaphene at 0, 4, 20, 100 or 500 ppm (0, 0.35, 1.8, 8.6, and 45.9 mg/kg 
for males, and 0, 0.5, 2.6, 12.6 or 64 mg/kg for females, respectively) for thirteen 
weeks.  No effects were noted in clinical signs or among rats dying spontaneously.  
The only effects noted were on the liver/body weight ratio and hepatic microsomal 
enzyme activities, which were increased in both sexes fed 500 ppm.  Toxaphene 
caused kidney enlargement in male, but not female rats.  Histological changes were 
noted in the kidney, liver and thyroid. 
Chu et al. (1986) also evaluated the toxicity of toxaphene on dogs.  Groups of six 
male and female dogs were administered toxaphene via gelatin capsules at doses of 
0, 0.2, 2.0, or 5.0 mg/kg-day each day for 13 weeks.  There was an inadvertent 
increase in the dose at the 2.0 mg/kg-day level.  Food consumption and growth rate 
were not affected.  Mild to moderate dose-dependent histological changes were 
noted in the kidney and thyroid.  Large eosinophilic inclusions were found in the 
kidneys of high-dose males while cytoplasmic vacuolation was found in the mid- and 
high-dose groups.  Thyroid changes included a mild increase in epithelial height and 
reduced colloid density.  Based on these findings, the authors (Chu et al., 1986) 
proposed a subchronic NOAEL of 0.35 mg/kg for the rat and 0.2 mg/kg for the dog. 
Cardiac Toxicity 
There appears to be no specific pattern of action for toxaphene on the heart.  In one 
case, acute administration of toxaphene (up to 400 mg/kg) to rats resulted in 
capillary congestion and capillary hemorrhage in the hearts, but this was probably 
the result of an inflammatory response (Boyd and Taylor, 1971).  In another instance 
an acute dose (>10 mg/kg) appeared to increase heart rate without other vascular 
effects (Lackey, 1949).  For the most part, in acute, subchronic and chronic studies, 
toxaphene had no specific effect on the heart. 
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Gastrointestinal Toxicity 
Chronic administration of toxaphene to rats and mice was noted to cause abdominal 
distension and diarrhea (NCI, 1977).  This study is described in detail in the Chronic 
Toxicity section. 
Renal Toxicity 
Toxaphene has been reported to cause renal toxicity.  In dogs, dosing of 5 mg/kg for 
106 days resulted in degeneration of kidney tubules (Lackey, 1949).  In subchronic 
studies conducted in rats and dogs (Chu et al., 1986), toxaphene, at doses ranging 
from 8.6 to 12.5 mg/kg-day, caused moderate toxicity to the proximal convoluted 
tubules of male rats, while other effects (including increased kidney weight) 
occurred at doses up to 63 mg/kg-day in female rats.  Dogs of both sexes receiving 
up to 5 mg/kg were seen to have eosinophilic inclusions occasionally accompanied 
by focal necrosis.  In a chronic rat study (Ortega et al., 1957), no adverse effects 
were noted on the rat kidneys.  In a two-year-old boy poisoned by toxaphene, 
swelling of the kidney was noted (McGee et al., 1952). 
Genetic Toxicity 
The many genotoxicity evaluations of toxaphene are summarized in Table 2 below.  
Toxaphene appears to be more genotoxic in the in vitro test systems than in the 
in vivo systems.  In the Ames test, toxaphene has been found to be positive.  
Generally, rates of mutagenic activity significantly increased only with higher 
concentrations (500 µg/plate in Schrader et al., 1998).  The addition of metabolic 
activators generally diminished the number of revertants (Schrader et al., 1998; 
Mortelmans et al., 1976).  Steinburg et al. (1998) noted that toxaphene was 
mutagenic in TA98 (only at 10,000 µg/plate) and in TA100 strains at all 
concentrations (lowest, 156 µg/mL) in plate systems.  However, in a 
microsuspension/preincubation assay, toxaphene was not mutagenic to TA98, and 
mutagenic to strain TA100 only at concentrations of 2500, 5000, and 10000 µg/L 
(Steinburg et al., 1998). 
In mammalian systems, toxaphene has been shown to increase sister chromatid 
exchanges (SCEs) in two of three assays.  Sobti et al. (1983) noted increased sister 
chromatid exchanges in the human lymphoid LAZ-007 cell line under both activated 
and non-activated conditions, with the activated cultures having fewer SCEs than the 
non-activated.  The mammalian mutational assays have generally not been consistent 
indicators of toxaphene mutagenicity.  Unfortunately, toxaphene has not been 
adequately evaluated under even a limited screening battery. 
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Table 2.  Genotoxicity of Toxaphene (Adapted from ATSDR, 1997) 
In vitro test systems  Results 
(without activation / with 
activation) 
Reference 
E1 plasmid DNA isolated 
from E. coli 
- / ND  Griffen et al., 1978 
S. typhimurium  TA98  + / ND  Hooper et al., 1979 
S. typhimurium  TA100  - / +  Hooper et al., 1979 
S. typhimurium  TA98  + / (+)  Mortelmans et al., 1986 
S. typhimurium  TA100  + / +  Mortelmans et al., 1986 
S. typhimurium  TA 1535  - / - Mortelmans et al., 1986 
S. typhimurium  TA100  (+) / - Mortelmans et al., 1986 
S. typhimurium TA 97  + / (+)  Schrader et al., 1998 
S. typhimurium TA 98  + / (+)  Schrader et al., 1998 
S. typhimurium TA 100  + / +  Schrader et al., 1998 
S. typhimurium TA 102  (+) / (+)  Schrader et al., 1998 
S. typhimurium TA 104  + / (+)  Schrader et al., 1998 
S. typhimurium TA 98  + / ND  Steinburg et al., 1998 
S. typhimurium TA 100  + / ND  Steinburg et al., 1998 
HGPRT induction  - / - Schrader et al., 1998 
SCE in V79  - / - Schrader et al., 1998 
SCE in human lymphoid 
cells 
+ / +  Sobti et al., 1983 
Neurospora crassa  + / ND  Mortelmans et al., 1986 
SCE induction  +  Steinel et al., 1990 
In vivo test systems 
Human lymphocytes  + / ND  Samosh, 1974 
Peroxisome proliferation  - Hedli et al., 1998 
32P-Postlabeling - Hedli  et al., 1998 
Mouse dominant lethal   - / ND  Epstein et al., 1972 
+ = positive, - = negative, (+) = weakly positive, ND = no data 
The ability of toxaphene to form DNA adducts and to induce peroxisome 
proliferation were investigated as potential mechanisms for toxaphene induced-liver 
tumorigenicity.  Groups of three or four male CD1 mice were treated by oral 
intubation with 10, 25, 50 or 100 mg/kg toxaphene in corn oil for seven consecutive 
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days (Hedli et al., 1998).  Negative control mice received corn oil alone; positive 
control mice were treated with 200 mg/kg clofibrate.  All animals were sacrificed 
24 hours after the last treatment.  Livers from two animals per group were pooled 
and evaluated for specific isoenzyme CYP 4A1 of cytochrome P-450 with an 
immunodetection assay.  This isoenzyme is associated with peroxisomal 
proliferation.  No induction of this isoenzyme was noted, although total liver weight, 
cytochrome P-450, and cytochrome b5 were increased over controls.  Livers of the 
other treated animals were extracted and subjected to a 
32P-post labeling assay to 
detect DNA adduct formation.  No increases in DNA adduct formation were noted.  
The totality of the evidence suggests that toxaphene is genotoxic. 
Developmental and Reproductive Toxicity 
The reproductive effects of toxaphene were evaluated in a two-generation study (Chu 
et al., 1988).  Groups of 30 female and 15 male weanling rats were given toxaphene 
in their diets at 0, 4, 20, 100 or 500 ppm solubilized in corn oil.  Toxaphene did not 
have any effects on litter size, pup weight, fertility or gestation and survival indices.  
Toxic effects in treated animals occurred primarily in the 500 ppm group and 
included depressed weight gain, elevated serum cholinesterase and increased liver 
and kidney weight and hepatic microsomal enzyme activities.  Morphological 
changes were seen in the thyroid, liver and kidney.  Minor effects were observed at 
lower doses, down to 20 ppm, but it was not clear that these minor effects were 
necessarily dose-related.  In the thyroid, two adenomas were observed at the highest 
dose.  In the liver, minimal to mild changes occurred in the cytoplasmic density, 
homogeneity, and vacuolation, with severity increasing with dose.  In the kidney, 
dose-dependent injuries were observed in the proximal tubules of both generations of 
male rats, mostly at the level of cytoplasmic changes, which increased in severity 
with dose. 
In a three-generation study (Kennedy et al., 1973) male and female rats were fed 
diets containing 0, 3, 10, 25 or 100 ppm toxaphene for 39-42 weeks.  There were no 
effects on litter sizes, pup survival or weanling body weights.  There was a slight 
cytoplasmic vacuolization in the livers of parental animals at the highest 
concentration (corresponding to doses of about 5 mg/kg-day according to ATSDR, 
1996), but no effects were seen in growth, survival, clinical parameters, or organ 
weights. 
In another multigenerational study, mice were fed a diet of 25 ppm of toxaphene 
(3.25 mg/kg-day according to ATSDR, 1996) during mating, gestation and lactation, 
and pups received it after weaning.  No effects on lactation, reproduction, average 
litter size, or offspring growth and viability were noted for five generations of mice 
(Keplinger et al, 1970).  Male rats administered toxaphene at 2.4 mg/kg-day for six 
months had no effects on their circulating testosterone levels (Peakall, 1976). 
Administration of 0, 15, 25, or 35 mg/kg-day of toxaphene to rats by gavage in oil 
during gestation days 7 through 16 increased fetal mortality at all doses.  There was a 
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dose-related reduction in maternal weight gain and in the average number of sternal 
ossification centers in fetuses (Chernoff and Carver, 1976).  No major anatomical 
defects were noted in this study or in several others in which toxaphene was 
administered gestationally at doses ranging from 0.05 to 75 mg/kg-day (Allen et al., 
1983; Chernoff and Kavlock, 1982; Crowder et al., 1980; Kavlock et al., 1982; 
Kennedy et al., 1973 and Olson et al., 1980). 
Immunotoxicity 
Toxaphene has been reported to induce specific humoral immunosuppressive effects.  
Male rats exposed to 1.5 mg/kg toxaphene in feed for nine weeks had impaired IgG 
production at some stages of the IgG response (Koller et al., 1983).  Similarly, 
female mice had impaired IgG production after being fed toxaphene for eight weeks 
at concentrations of 100 and 200 ppm (approximately 15 and 30 mg/kg-day) but not 
at 10 ppm (about 1.5 mg/kg-day)(Allen et al., 1983). 
Cell-mediated responses were also assessed in toxaphene-exposed animals.  
Weanling female mice were fed 10, 100 and 200 ppm (approximately 1.5, 15 and 
20 mg/kg-day) of toxaphene in the diet (Allen et al., 1983).  No differences in 
response between treated and control animals were noted by the delayed-type 
hypersensitivity assay.  Acute administration of 7.5 mg/kg toxaphene in the diet was 
reported to decrease thymus weight in rats (Trottman and Desaiah, 1980).  However, 
the administration of 5 mg/kg-day toxaphene for 39-42 weeks to rats did not have an 
effect on spleen or thymus weights (Kennedy et al., 1973). 
Neurotoxicity 
Central nervous system stimulation is an important effect of short-term exposure to 
toxaphene.  Dogs administered 10 mg/kg of toxaphene for two days by stomach tube 
showed convulsions.  Dogs receiving 4 mg/kg-day for 106 days by stomach tube had 
intermittent convulsions (Lackey, 1949).  Olson et al. (1980) reported behavioral 
effects (retarded maturation based on a swimming test) in juvenile rats after prenatal 
treatments (to the dams) at 0.05 mg/kg-day. 
The effects of toxaphene and parathion on rats exposed peri- and postnatally were 
examined (Crowder et al., 1980).  In the postnatal study with toxaphene alone, 
females received daily oral doses of 6 mg/kg for 21 days.  In the perinatal study, 
females received 6 mg/kg daily from day 7 of pregnancy until parturition.  No weight 
changes or increases in mortality were noted.  Perinatal exposure did not cause 
significant differences in grasp-hold, startle, or initiation of the righting reflex.  
There were also no significant differences in maze learning and transfer of this 
learning (ability to learn the maze in reverse) with either post- or perinatally-exposed 
animals.   
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Endocrine Toxicity 
Results from animal studies suggest that prolonged oral exposure to toxaphene may 
induce thyroid injury (Chu et al., 1986; NCI, 1977).  Specifically, increased 
incidences of thyroid follicular cell adenomas were noted in male rats upon chronic 
exposure (NCI, 1977).  In another study (Waritz et al., 1996), 40 male rats were 
given an oral dose of 100 mg/kg-day toxaphene for three days, then 75 mg/kg-day 
daily for an additional 25 days.  After 0, 7, 14 and 28 doses, 20 test and 10 vehicle-
control animals were sacrificed for gross and histopathological examination of 
thyroid, parathyroid and pituitary glands.  There was a significant time related 
increase in serum TSH levels, but no increase in serum levels, T3, T4, rT3, and 
corrected T3.  Thyroid and pituitary gland weights, and thyroid and pituitary to brain 
weight ratios were not significantly affected.  The incidence of thyroid follicular cell 
hypertrophy and intrafollicular hyperplasia were increased, and thyroid colloid stores 
were decreased with treatment.  The authors reported that the results were consistent 
with increased production and turnover of T3 or T4 resulting from induction of 
cytochrome P450 and UDP-glucuronyl transferases. 
Chronic Toxicity/ Carcinogenicity 
Chronic toxicity of toxaphene was evaluated in rats by Treon et al. (1950).  Four 
groups of 20 male and female rats were fed toxaphene in the diet at 10, 100, 1000 or 
1500 ppm.  After 7 1/2 months to 10 months, rats in the 1500 ppm group and some 
in the 1000 ppm group suffered convulsions.  There were no significant effects on 
mortality or on the hematopoietic system.  Liver weight and liver to body weight 
ratios were increased in the 1000 and 1500 ppm groups.  Upon examination, liver 
cells showed swelling and hypertrophy and proliferation of the smooth endoplasmic 
reticulum.  This occurred mostly in the 1500 ppm group and only to a slight extent in 
the 1000 ppm group. 
In a study evaluating the toxicity of four organochlorine pesticides, six male and six 
female Sherman rats were fed 50 and 200 ppm toxaphene (estimated to be 2.5 and 
10 mg/kg by ATSDR, 1996) in the diet for up to 9 months (Ortega et al., 1957). 
There were control groups of 25 male and 16 female rats for this study.  No clinical 
signs of toxicity and no effects on body weight gain, food intake, or liver weights 
were noted.  No histological changes were seen in the kidney or spleen.  Three of the 
12 rats in the 50 ppm group showed histological changes in the liver consisting of 
centrilobular cell hypertrophy, peripheral migration of cyanophilic granulation and 
the presence of liposphere inclusion bodies.  Six out the 12 rats fed 200 ppm showed 
liver changes. 
Groups of rats fed toxaphene in the diet at 25, 100, or 400 ppm (approximately 1, 5, 
20 mg/kg, respectively for their lifetime) showed minor changes only to the liver at 
100 ppm, and liver enlargement at 400 ppm levels (Fitzhugh and Nelson, 1951). 
Toxaphene was administered to 9 dogs daily for 5 days a week at doses of 5, 10, or 
25 mg/kg with maize oil in gelatin capsules.  The dose of 25 mg/kg was fatal to all 
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three of the dogs treated with this dose.  A dose of 10 mg/kg caused one dog to die 
within 33 days, while the other at this dose survived and was sacrificed after 
3½ years.  Four dogs survived a dose of 5 mg/kg for four years before being 
sacrificed (Lehman, 1952).  Dogs receiving the 5 mg/kg dose were judged to be free 
of overt effects. 
Treon et al. (1950) fed toxaphene six days/week for two years to three male and five 
female dogs, beginning when they were four months old.  Toxaphene was added to 
the diet and in their drinking water at levels of 10 or 50 ppm.  The equivalent daily 
dose was approximately 0.60 to 1.47 mg/kg-day or 3.12 to 6.56 mg/kg-day, 
respectively, based on WHO (1984) estimates.  There were no reported effects on 
behavior, mortality, hematology, gross pathology, organ to body weight ratios and 
histopathology.  There were increases in liver weights, liver to body weight ratios, 
and moderate liver degeneration at the higher dose.  At the lower dose, liver changes 
included enlargement, slight granularity and vacuolization of the cytoplasm.  
In the same study, toxaphene was given to two monkeys in their diet for 6 days per 
week for two years at a dose of 0.64- 0.78 mg/kg (Treon, 1950).  No signs of toxicity 
were noted in growth rates, body weights, organ weights, organ weight ratios and 
histological examination of tissues.  
The National Cancer Institute (NCI) commissioned a long-term toxicity study of 
toxaphene on rats and mice (NCI, 1977).  In the rat study, 50 Osborne-Mendel male 
or female rats per group were treated with toxaphene at two concentrations 
administered in the diet for 80 weeks.  The initial levels for males were 1280 ppm 
and 2650 ppm at the low and high levels, respectively.  After observing significant 
toxicity, the concentrations were lowered to 640 and 1280 ppm at two weeks, and 
then again to 320 and 640 ppm, respectively at 53 weeks.  The time-averaged 
concentration levels were computed to be 556 and 1112 ppm, respectively for the 
low and high groups.  The female rats received initial concentrations of 640 and 
1280 ppm, but were lowered to 320 and 640 ppm at 55 weeks.  The time-averaged 
concentrations for females were 540 and 1080 ppm.  At 80 weeks, all animals were 
switched to a control diet without corn oil for 20 weeks, followed by an additional 
8 weeks on a diet with corn oil.  The study utilized only 10 matched controls.  To 
conduct statistical analyses, data from control groups from other NCI experiments 
were pooled as additional controls for this experiment. 
Treatment with toxaphene resulted in decreased body weight, generalized body 
tremors, leg paralysis, ataxia, epistaxis, hematuria and vaginal bleeding.  There was a 
significant increase of follicular carcinomas or adenomas of the thyroid in both male 
and females in the high dose group, with a dose-related trend across all doses.  In 
males the tumor incidences were 1/7 for matched controls, 2/44 for pooled controls, 
2/44 for the low level, and 7/41 for the high level.  In females, the tumor incidences 
were 0/6 for matched controls, 1/46 for pooled controls, 1/43 for the low level and 
7/42 for the high level.  Two follicular–cell tumors in the high-dose males were 
carcinomas, the rest (in males) were adenomas.  In females, the incidence of 
follicular-cell adenomas of the thyroid was dose-related using either the matched or 
pooled controls.  In females, the incidences of pituitary tumors were 3/8 for matched 
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controls, 17/51 for pooled controls, 15/41 for the low level and 23/39 for the high 
level.  The pituitary tumor incidences were significantly higher in high-dose females 
compared to the pooled control group (p<0.05 by Fisher’s exact test).  However, due 
to the high incidence of pituitary tumors in historical controls (sometimes as high as 
60 percent), it could not be concluded that toxaphene administration was associated 
with this apparent increase in pituitary tumors.  NCI noted that “the test results also 
suggest that toxaphene is carcinogenic to the thyroid of male and female Osborne-
Mendel rats.” 
In the NCI mouse study (1977), groups of 50 B6C3F1 male or female mice were 
administered toxaphene in the diet for 80 weeks.  The initial concentrations were 160 
and 320 ppm for the low and high concentration groups, respectively.  These 
concentrations were lowered to 80 and 160 ppm, respectively, after 19 weeks.  Thus, 
the time-averaged concentrations for the low and high dose groups were 99 and 
198 ppm, respectively.  Administration at this concentration continued to 80 weeks, 
at which time animals were switched to a control diet without corn oil for 7 weeks, 
then to diets with 2 percent corn oil for an additional 3-4 weeks.  As with the rats, 
matched and pooled controls were used in statistical evaluations.  Toxicity observed 
included abdominal distension, diarrhea, dyspnea, and rough hair coats.  The 
incidence of hepatocellular carcinomas showed a dose-related increase.  For males 
the incidences were 0/10 for matched controls, 4/48 for pooled controls, 34/49 for 
low dose, and 45/46 for high dose.  For females the incidences were 0/9 for matched 
controls, 0/48 for pooled controls, 5/49 for the low level, and 34/49 for the high level 
groups.  NCI concluded that “under the conditions of this bioassay, toxaphene was 
carcinogenic in male and female B6C3F1 mice causing increased incidences of 
hepatocellular carcinomas.”  
Litton Bionetics (1978) conducted a longer-term carcinogenicity study in B6C3F1 
mice.  Groups of 53-54 male or female mice were treated with toxaphene in corn oil 
at 0, 7, 20 or 50 ppm in the diet.  Treatment continued for 18 months at which time 
mice were returned to a control diet for 6 months before termination.  It should be 
noted that only the liver and other tissues showing gross pathology were examined 
histologically.  Survival was 83-90 percent in male mice and 83-87 percent in female 
mice, and was not dose-related.  Incidences of hepatocellular carcinomas at 0, 7, 20 
and 50 ppm were 7/53, 11/54, 12/53 and 12/51 in male mice, and 1/53, 1/53, 3/52 
and 3/52 in female mice, respectively.  Incidences of hepatocellular adenomas were 
reported at 3/53, 0/54, 2/53 and 11/51 in male mice and 1/53, 1/53, 1/52 and 3/52 in 
female mice for the 0, 7, 20, and 50 ppm groups, respectively.  Combining the 
adenomas and carcinomas, the increased tumor incidence was significant only for the 
high dose males and not for any other group, including females. 
Triolo et al. (1982) conducted a study on 12 female A/J mice treated with toxaphene 
in corn oil in the diet at 0, 100 or 200 ppm (only 11 mice) for 12 weeks.  In a 
20-week study, 17 female A/J mice were fed 200 ppm toxaphene in the diet, while 
17 controls received only corn oil.  Histological examinations were limited to 
detection of only lung and forestomach tumors.  In the 12-week study, at 200 ppm, 
one lung tumor was found among six treated mice, but no forestomach tumors.  In 
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the 20-week study, one lung tumor was found in 15 treated mice and one in control 
mice and no forestomach tumors.  Due to the limited nature of this study (short study 
period and limited examination) very little can be concluded about the carcinogenic 
potential of toxaphene from these results. 
Toxicological Effects in Humans 
Acute Toxicity 
Toxaphene is acutely toxic to humans.  Several fatalities have been documented by 
McGee et al. (1952).  In these cases an unknown quantity of toxaphene was ingested, 
either intentionally, or accidentally from food contamination.  Reported symptoms 
included convulsions without abdominal pain, vomiting and diarrhea.  In one death, 
congestion and edema of the lungs was observed.  Death was attributed to respiratory 
failure resulting from seizures. 
Subchronic Toxicity 
Keplinger (1963) exposed 25 adults (15 males and 10 females) to an aerosol 
containing toxaphene at a maximum concentration of 500 mg/m
3 for 39 minutes 
daily for 10 days.  The author calculated an exposure dose to be as much as 
60 mg/person/day.  Three weeks after the last exposure, subjects were exposed for 
three more 30-minute periods.  Follow-up examination of the skin, blood tests and 
urinalysis revealed no effects. 
Genetic Toxicity 
Lymphocytes cultured from eight women exposed occupationally to an unknown 
amount or concentration of toxaphene were examined for chromosomal breaks 
(Samosh, 1974).  A higher incidence of chromosomal breaks was reported in 
exposed women (13.1 percent) compared to unexposed controls (1.6 percent). 
Neurotoxicity/Behavioral 
In three women who ate collard greens contaminated with toxaphene, convulsive 
seizures were followed by periods of memory loss (as much as a week later).  The 
day following the convulsions, there were no reported ill effects other than 
weakness.  The lowest estimated dose for inducing convulsions was 9.5 mg/kg 
(McGee et al., 1952). 
Chronic Toxicity/Carcinogenicity 
Several epidemiological or case studies were located on the chronic effects of 
toxaphene exposure to humans from occupational exposure.  However, these are 
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difficult to interpret based on the inability to estimate exposures to toxaphene or the 
concurrent exposure to other pesticides, which could impact the results. 
Barthel (1981) reported a study of 1658 male agricultural workers and agronomists 
exposed to toxaphene and other pesticides between 1954 and 1972.  A total of 
169 malignant neoplasms was observed and a higher proportion of bronchial 
carcinoma was found, compared with the unexposed general population; 
59 (35 percent) observed as compared to 42 (24 percent) expected, with a standard 
mortality ratio (SMR) of 2.  The authors did not think that toxaphene among all the 
pesticides involved was responsible for tumor induction. 
IARC (1979) reported two cases of aplastic anemia associated with dermal exposures 
to toxaphene and lindane mixtures.  One case terminated in death due to acute 
myelomonocytic leukemia. 
DOSE-RESPONSE ASSESSMENT 
Noncarcinogenic Effects 
Toxaphene is known to be toxic to the lung, liver, kidney, nervous, hematopoietic 
system and thyroid under longer-term to lifetime exposure.  Toxaphene is also 
associated with an increased cancer incidence and early death in experimental 
animals. 
Several lifetime studies of Toxaphene toxicity have been conducted over the years, 
however none were judged to be suitable to serve as the basis for noncarcinogenic 
risk assessment.  This assessment is based on the fact that there are study limitations 
that included intrastudy dose adjustments, inadequate assessment of noncancer 
effects and small group sizes.   In the Litton study (1978), no attempt was made to 
systematically evaluate all tissues, and only those exhibiting “gross pathology” were 
examined.  In the NCI (1979) study conducted in rats, increased incidences of 
dyspnea, abdominal distension, diarrhea, hematuria, alopecia, and dermatitis were 
reported at 27 mg/kg-day (estimated after dose-adjustment) with a trend toward 
increased mortality.  
In studies conducted pre-1960, very little information is provided to allow for 
reasonable dose extrapolation, and the use of single doses or small group sizes does 
not make these studies prime candidates for risk evaluation.  Approximated doses for 
which no effects are noted range from 0.5 mg to 5 mg/kg-day for these studies.       
Most subchronic studies have limitations similar to those found in the chronic studies 
for developing reasonable estimates of doses producing minimal to no effects.  
However the subchronic studies reported by Chu et al (1986) are of higher quality 
and more suitable for risk assessment purposes.  
Two subchronic studies reported by Chu et al. (1986, 1988) found effects associated 
with toxaphene exposure at lower doses than those used in the NCI (1979) study.  
DRAFT FOR PUBLIC COMMENT 

AND SCIENTIFIC REVIEW  18  June 2002     
   
 
DRAFT
 
These studies provided the lowest LOAEL determinations of all the toxaphene 
experimental toxicity studies.  The Chu et al. (1986, 1988) studies provide NOAELs 
of 0.35 mg/kg-day for slight hepatic changes (increased liver weights) and 
0.18 mg/kg-day for changes to density of the rat thyroid (judged to be reversible).  In 
the study of Chu et al. (1986), a NOAEL of 0.2 mg/kg-day was reported for biliary 
and hepatocellular changes in dogs, however there is uncertainty regarding the dose 
level because of an inadvertent increase in the dose during part of the study period.  
Carcinogenic Effects 
Toxaphene (polychlorinated camphene) was listed under the Safe Drinking Water 
and Toxic Enforcement Act of 1986 (Proposition 65) on January 1,1998 by the 
Science Advisory Panel as a chemical known to the State to cause cancer.  The 
Reproductive and Cancer Hazard Assessment Section of OEHHA calculated a 
cancer potency and a no significant risk level for Proposition 65 purposes based on 
carcinogenic effects noted in two rodent studies (OEHHA, 1988).  IARC (1979) and 
U.S. EPA (1999) have concluded that there is sufficient evidence to consider 
toxaphene an animal carcinogen, while at the same time there was insufficient 
evidence from human studies.  As a result, toxaphene is classified in category 2B 
(“possibly carcinogenic to humans”) by IARC (1987) and was placed in category B2 
(“probable human carcinogen”) by U.S. EPA (1987). 
There is no new evidence since the OEHHA (1988) assessment that diminishes 
concern regarding the carcinogenicity of toxaphene.  New evidence reported since 
then does not support a change to the potency estimate generated in the 1988 
assessment. 
CALCULATION OF THE PHG 
Calculations of concentrations of chemical contaminants in drinking water associated 
with negligible risks for carcinogens or noncarcinogens must take into account the 
toxicity of the chemical itself, as well as the potential exposure of individuals using 
the water.  Tap water is used directly as drinking water, as well as for preparing 
foods and beverages.  It is also used for bathing or showering, and in washing, 
flushing toilets and other household uses resulting in potential dermal and inhalation 
exposures.  In this case, certain toxaphene components may be volatile enough to 
consider inhalation as a possible exposure route from use of domestic water.  
However, the contribution to inhalation exposure from these (semi-) volatile 
components would be small, and difficult to estimate.  Toxaphene is dermally 
permeable; however the amount potentially absorbed from the brief-duration 
household water uses would be marginal when compared to the amount absorbed 
from inhalation or ingestion of drinking water. 
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Noncarcinogenic Effects 
Calculation of a public health-protective concentration (C, in mg/L) for toxaphene in 
drinking water for noncarcinogenic endpoints follows the general equation: 
C  = 	 NOAEL/LOAEL x BW x RSC
    U F  x  L / d a y 
where, 
NOAEL/LOAEL = 	no-observed-adverse-effect-level or lowest-observed-adverse­
effect-level; 
BW  = 	 adult body weight (a default of 70 kg); 
RSC  = 	 relative source contribution (a default of 20 to 80 percent); 
UF  = 	 uncertainty factors (typical defaults of 10 to account for inter­
species extrapolation, 10 for uncertainty from the subchronic 
nature of the principal study, and 10 for human variability); 
L/day  = 	 adult daily water consumption rate (a default of 2 L/day). 
Chu et al. (1986) fed 10 male and female rats diets containing toxaphene at 0, 4, 20, 
100 or 500 ppm for thirteen weeks.  Based on the calculation made by the authors, 
the doses were estimated to be 0, 0.35, 1.8, 8.6 or 45.9 mg/kg-day for males and 0, 
0.5, 2.6, 12.6 or 63 mg/kg-day, respectively, for females.  The only effects noted 
were on the liver/body weight ratio and hepatic microsomal enzyme activities, which 
were increased in both sexes fed 500 ppm.  Treatment-associated histopathology was 
noted at 20 ppm and above in the kidney, liver and thyroid, and was more prevalent 
in males.  Mild changes were seen at the 4 ppm level (0.35 mg/kg-day for male rats), 
but was comparable to controls.  Thus the NOAEL for this study would be 
0.35 mg/kg-day.  The health-protective concentration is therefore calculated as:  
C  =  0.35 mg/kg-day x 70 kg x 08
 1000 x 2 L/day 
=  0.0098 mg/L   =  10 µg/L (rounded)  =  10 ppb 
The above calculation utilizes the default values for body weight and drinking water 
consumption, and uncertainty factors of 10 to account for inter-species extrapolation, 
10 because of the subchronic nature of the principal study, and 10 for human 
variability.  The use of an RSC of 0.8 assumes that nearly all of the toxaphene that is 
available for human exposure would be from the drinking of water.  Toxaphene and 
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its metabolites are still being found as residues in a number of foodstuffs, 
particularly seafood, but are not anticipated in agricultural products.  Levels in 
seafood have been decreasing in frequency of occurrence and amount.  Although the 
exact contribution cannot be estimated, food is no longer considered a predominant 
source of toxaphene and therefore a higher RSC can be used to account for 
toxaphene predominantly from a water source. 
The resultant estimated public health protective level for noncarcinogenic effects 
would be 10 ppb. 
Carcinogenic Effects 
For carcinogens, the following general equation can be used to calculate the public 
health-protective concentration (C) for a chemical in drinking water (in mg/L): 
C  =  BW  ×  R  =  mg/L 
q1* or CSF  ×  L/day 
where, 
BW  = 	 adult body weight (a default of 70 kg); 
R = 	 de minimis level for excess lifetime individual cancer risk (a 
default of 10
-6); 
q1* or CSF  = 	 the q1* is the upper 95 percent confidence limit on the cancer 
potency slope calculated by the LMS model, and CSF is a potency 
derived from the lower 95 percent confidence limit on the 
10 percent (0.1) tumor dose (LED10), CSF = 0.1/ LED10; both 
potency estimates are converted to human equivalent dose [in 
(mg/kg-day)
-1] using BW
2/3 scaling; 
L/day  = 	 daily volume of water consumed by an adult (a default of two 
L/day or other volume in Leq/day to account for additional 
inhalation and dermal exposures from household use of drinking 
water as explained above). 
Pursuant to the listing of toxaphene as a chemical known to cause cancer under 
Proposition 65, the Reproductive and Cancer Hazard Assessment Section of OEHHA 
in 1988 calculated a cancer potency (OEHHA, 1988).  OEHHA proposed a health-
protective level in 1991 based upon the Proposition 65 evaluation of the carcinogenic 
potency of toxaphene (OEHHA, 1991).  No additional information on cancer 
associated with toxaphene exposure has become available to warrant revision of the 
1988 OEHHA potency estimation. 
DRAFT FOR PUBLIC COMMENT 
AND SCIENTIFIC REVIEW  21  June 2002     
   
   
 
 
 
 
DRAFT
 
The following narrative from the OEHHA (1988) document summarizes the 
derivation of the cancer potency estimate: 
“The Litton (1978) study on B6C3F1 mice consisted of a concurrent control 
group of 53 animals and three dose groups at 7, 20, or 50 ppm in the diet for 
18 months.  The average daily doses are calculated to be 0.84, 2.4, and 
6.0 mg/kg-day based on the assumption that 1 ppm of a chemical in feed is 
equivalent to 0.12 mg/kg-day, respectively.  An increase of hepatocellular 
carcinoma incidences was observed in treated male mice but not in female 
mice.  The tumor incidences were 10/53, 11/54. 12/53 and 18/51 for the male 
control, 7 ppm, 20 ppm and 50 ppm treatment groups, respectively.  Fitting 
the multistage polynomial to this bioassay data results in a cancer potency for 
animals (qanimal) of 0.905 (mg/kg-day)
-1, and for humans (qhuman) of 
1.2 (mg/kg-day)
-1.” 
Using the NCI mouse and rat study, OEHHA also calculated potencies for thyroid 
and follicular cell carcinomas or adenomas for male rats, resulting in cancer 
potencies (qanimal) of 5.0 x 10
-2 and 5.6 x 10
-2 (mg/kg-day)
-1 for matched controls and 
pooled controls, respectively.  OEHHA determined that the NCI (1979) study was 
less reliable for potency estimation than the Litton (1978) study.  The Litton (1978) 
study was conducted with groups fed much lower concentrations of toxaphene than 
those used in the NCI study.  The NCI (1979) study also had doses adjusted lower 
during the course of the study, resulting in greater uncertainty over the dose-
response.  Furthermore, there were fewer concurrent controls in the NCI (1979) than 
in the Litton (1978) study.  Therefore OEHHA concluded that the Litton (1978) 
study was better for risk extrapolation.  U.S. EPA (1987) also based its dose 
estimates on the Litton (1978) study. 
The current evaluation uses the same rationale for estimating a human health 
protective level as used earlier (OEHHA, 1991), which was described as follows: 
“DHS has evaluated two major bioassays for toxaphene (Litton, 1978; NCI, 
1979) and concluded that the Litton (1978) study is more reliable for potency 
determination, because toxaphene was tested at a lower dose and in more 
dose groups….  The cancer potency (q1*human) estimated from the incidences 
of hepatocellular carcinomas is 1.2 (mg/kg-day)
-1.  The DHS and EPA 
potencies are very similar.  Based on the cancer potency of 1.2 (mg/kg-day)
-1, 
using the default assumption that a 70-kg adult consumes 2 L of water a day, 
the RPHL is 30 ng/L (30 ppt).” 
Because the human health protective level calculated based upon carcinogenic 
endpoints (30 ppt, 0.03 ppb) is considerably lower than that calculated from 
noncarcinogenic endpoints (10 ppb), the lower value has been selected as the basis 
for the PHG.  
Therefore, OEHHA proposes that the PHG be set at 0.03 ppb. 
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RISK CHARACTERIZATION 
When no additional information is available to characterize the human risk of a 
chemical, the results of previous OEHHA assessments are used.  Such is the case for 
toxaphene.  There is no substantive new information that would warrant revision of 
the cancer potency estimates of the 1988 Proposition 65 risk assessment. 
The primary sources of uncertainty lie in the strength of the underlying data and the 
nature of risk extrapolation.  With toxaphene there is substantial evidence from 
animal experimental studies to indicate that toxaphene is carcinogenic.  This 
evidence consists of three chronic studies, some of which are of less than adequate 
quality based on current standards for chronic FIFRA studies.  There is no 
conclusive evidence for carcinogenicity of toxaphene in limited human studies.  
Mutagenicity and genetic toxicity testing indicates toxaphene is probably mutagenic.  
Toxaphene is considered a probable human carcinogen by the U.S.EPA (1985, 1998) 
and as a possible human carcinogen by IARC (1987), and is classified as a substance 
known to the state to cause cancer under Proposition 65 (OEHHA, 1988). 
To derive the potency values, OEHHA used the 95 percent upper confidence limit 
estimate of the linearized multistage model.  This is still the most common 
extrapolation method currently used, but it is also recognized that it probably 
overestimates the risk. 
The risk computation for drinking water from OEHHA (1991) was very similar to 
that calculated by U.S. EPA, as the following narrative from OEHHA (1991) 
explains: 
“EPA proposed a MCLG of zero and a MCL of 3 x 10
-2 mg/L or 30 ng/L 
(30 ppt).  The cancer potency (q1*human) reported in IRIS is 1.1 (mg/kg-day)
-1, 
which was derived from the combined tumor incidences of hepatocellular 
carcinomas and neoplastic nodules in the Litton (1978) mouse study.  The 
concentration of toxaphene in drinking water that poses a lifetime cancer risk 
of 10
-6, as calculated based on this cancer potency using the default 
assumption that a 70-kg adult consumes 2 L of water a day, is 32 ng/L, which 
was rounded off to 30 ng/L (30 ppt).” 
The slight difference (before rounding) between these two estimates (U.S. EPA and 
OEHHA) is because U.S. EPA assumed that one ppm of toxaphene in the diet is 
equivalent to 0.13 mg/kg-day and OEHHA assumed that it was 0.12 mg/kg-day 
(OEHHA, 1988).  However, the final U.S. EPA MCL for toxaphene is based on 
analytical considerations as explained in the next section. 
Recently Goodman et al. (2000) estimated another toxaphene cancer potency.  The 
authors selected the female liver tumor data set rather than the male liver tumor data 
set used by U.S. EPA and OEHHA in their toxaphene cancer potency assessments.  
The authors had an expert pathology working group reevaluate the NCI (1979) liver 
tumors on the basis of more current diagnostic criteria.  The group determined that 
some tumors could be reclassified.  The Litton (1978) tumor data could not be 
evaluated, as the slides/tissues were not available.  The authors felt justified to 
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combine the liver tumor data sets from the Litton and NCI studies (with reevaluated 
NCI data) based on their view that neither study alone was adequate for potency 
determination.  The authors presented an argument that toxaphene was not a 
genotoxic carcinogen, but ultimately estimated a cancer potency by linear 
extrapolation from the ED10 to the origin.  The resulting cancer potency was 
0.1 (mg/kg-day)
-1, which is 10-fold lower than the U.S. EPA and OEHHA potency 
estimates. 
Estimating potencies using the reevaluated data sets from the NCI studies in the 
multistage model (not combined with the Litton data) supports the earlier OEHHA 
and U.S. EPA finding that male mice are considerably more sensitive than female 
mice to the carcinogenic effects of toxaphene.  Goodman et al. (2000) argued that 
the background rate of the liver tumors in the control male mice was higher and more 
erratic compared with females, thus justifying the selection of female mice as the 
basis for the potency selection.  The Goodman et al. (2000) approach combines two 
data sets based on different evaluation guidelines, which the authors acknowledge as 
being incongruous, but justify their use on the reasoning that the tumor incidences 
are similar in both data sets.  However, OEHHA does not concur with this approach, 
and does not feel that there is sufficient evidence to consider toxaphene as a 
nongenotoxic carcinogen.  Therefore, the use of the linearized multistage model is 
retained for this evaluation, which is consistent with the assumption that toxaphene is 
genotoxic and is appropriate for cancer potency estimation using the multistage 
model. 
OTHER GUIDANCE VALUES AND REGULATORY 
STANDARDS 
Federal and state drinking water regulations for toxaphene in drinking water have 
been based on the potential carcinogenic hazards of toxaphene.  The federal 
Maximum Contaminant Level Goal (MCLG) for toxaphene is zero, and the MCL is 
0.003 mg/L for drinking water (U.S. EPA, 1991; 1999).  This MCL is based on the 
Practical Quantitation Limit (PQL) derived by the U.S. EPA (1991) and reflects the 
risk of toxaphene ingestion at the 10
-4 level risk level, applying the same human 
potency factor as mentioned before. 
A Maximum Contaminant Level (MCL) of 0.003 mg/L was established by the 
California Department of Health Services (DHS) (22 CCR 64444).  This value is 
identical to the U.S. EPA’s MCL for toxaphene, and is based on the same 
considerations.  The Agency for Toxic Substances Disease Registry (ATSDR, 1996) 
developed a long term Minimum Risk Level (MRL) of 0.001 mg/kg-day based on 
the subchronic study conducted by Chu et al. (1986).  It declined to derive a chronic 
duration MRL, stating there was insufficient information to do so. 
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